Organic Active Ingredients TRIZ Cases

Monocyte-binding aptamer lipid nanoparticles carry drugs or imaging agents into low-permeability tumors by using monocyte recruitment.

Separating cell-free and surface-bound nucleic acids and matching mutations to tissue maps helps localize disease signals from blood.

NK-92 membrane proteins give lipid nanocarriers tumor-targeting and longer circulation, improving MRI contrast delivery and early cancer imaging.

A fixed-dose ibuprofen salt and tramadol combination improves moderate to severe pain relief while limiting opioid-related adverse effects.

Pre-encapsulated vitamins and oils in composite hydrocolloid shells improve capsule formability and gummy stability during processing.

Sulfonylurea-substituted monocyclic β-lactams improve permeability and retain activity against β-lactamase-producing bacteria, including MBL strains.

Engineered E1A and E4 deletions make adenoviruses replicate in E2F-deregulated tumor cells while limiting normal-cell harm and antibody escape.

A faster-dissolving famotidine layer protects the stomach before ibuprofen acts, reducing heartburn and upset stomach during acute pain treatment.

Pyrazole pyrimidine derivatives inhibit CK1 and IRAK1 to address limited kinase targeting in cancer and inflammatory disease treatment.

Controlled lactic acid, insulin, and glucose delivery creates lactate-protected hypoglycemia that suppresses glycolysis-dependent cancer while limiting alkalosis.

Systemic cationic mRNA liposomes prime myeloid and T-cell activity, helping immune checkpoint inhibitors work in cold, resistant tumors.

Targeted side-chain substitutions in the enzyme release channel speed nicotine degradation 3.67-fold while preserving overall stability.

Linked NMN-like antiviral compounds raise intracellular NAD while treating viral infections, reducing the need for separate NAD and antiviral therapies.

Crystalline L-ornithine phenyl acetate lowers sodium load and osmotic pressure, enabling safer concentrated IV treatment for hepatic encephalopathy.

Roller compaction turns quercetin into high-density granules with better flow, lower excipient demand, and more uniform dosage forms.

Combining calcium pantothenate with dimenhydrinate boosts myogenesis-related protein expression to improve muscle growth and survival in myopathy models.

A porous scaffold recruits immune cells and pairs with immunogenic cancer cell death to boost adaptive immunity against established tumors.

A float-based spacer spirometer gives visual inspiratory flow feedback to improve inhaler actuation timing and lung drug deposition.

Selective viral vectors silence bladder afferent neurons to reduce involuntary contractions in NDO while preserving efferent bladder function.

A thick biodegradable polymer membrane enables sustained subcutaneous diffusion with flat plasma levels and self-elimination after drug depletion.

An L-glucose gold complex targets cancer cells, boosting RF heating at the tumor site while reducing toxicity to normal cells.

A quinoxalinedione and pyridopyrazinedione degrader targets BCL6 at lower effective concentrations for DLBCL and follicular lymphoma.

Blocking the CD40/CD154 pathway with humanized anti-CD40 antibodies suppresses B cell activation while reducing transplant rejection and toxicity.

Chemical modifications and carrier-linked siNA improve RNA stability and delivery compatibility while preserving RNAi gene silencing.

Immediate-release cedazuridine and enteric azacitidine improve oral bioavailability by limiting acid and CDA-driven degradation.

A synbiotic blend of lychee polyphenols, Bifidobacterium strains, and methionine raises GLP-1 to support weight management.

A combined riboflavin-biotin daily formulation boosts biotin biosynthesis and mucus thickness to help limit neuroinflammation linked to Parkinson's disease.

Specific ionizable lipid structures raise mRNA encapsulation and delivery efficiency, enabling dose-dependent protein expression without viral vector limits.

Heterocyclic compounds tuned at key substituent positions selectively inhibit Des1, modulating sphingolipid biosynthesis for fibrotic and inflammatory disease treatment.

Localized functionalized chitosan chelates excess metals to reduce inflammation and oxidative stress without systemic side effects.

A Tris-buffered furosemide formulation holds pH at 8.0-8.5 to enable higher drug concentration, lower injection volume, and stable delivery.

Dry-granulated oral formulations with 40-70 wt% Formula I raise drug loading while preserving manufacturability, stability, and patient compliance.

BAG3 therapy stabilizes cIAP1/2 and TOM22 to curb caspase-driven inflammation while preserving mitochondrial integrity.

High-pH concentrated 5,10-CH2-(6R)-THF solutions maintain purity and oxidation stability without buffers, reducing agents, or stabilizers.

Neutrophil membrane-coated RNA carriers target arterial injury, avoid organ sequestration, and help prevent restenosis without stents.

A glycan-headed copolymer polymersome uses disulfide-linked functional blocks to improve serum stability, selective APC delivery, and payload release.

High-dose sublingual dexmedetomidine in split dosing calms agitation while limiting sedation and cardiovascular side effects.

Phosphonate-containing heterocycles selectively inhibit TYK2 and JAK1 to treat related diseases while minimizing off-target JAK effects.

Combining CD163 antibodies with PD-1 or PD-L1 checkpoint inhibitors relieves T cell suppression and strengthens anti-cancer immune activity.

TCM-derived lipids protect small RNA from in vivo degradation while promoting cellular uptake and delivery to target tissues.

Ion-exchange resin binding helps NSAIDs dissolve rapidly in water, cutting dose volume while masking taste and chemesthetic irritation.

Chroman derivatives drive ubiquitin-proteasome ERα degradation while addressing the poor solubility and oral bioavailability of existing SERDs.

SBEβCD inclusion complexing and bicarbonate improve meloxicam absorption, enabling faster and sustained migraine relief with rizatriptan.

Position-specific nucleotide and linkage modifications help siNA resist degradation and penetrate target cells for more effective RNAi therapy.

Bone marrow lentiviral delivery with platelet-specific FVIII expression and transient immune suppression helps treat hemophilia A with inhibitors.

Selective heteroaryl NaV1.8 inhibitors widen the therapeutic window and improve pain relief by reducing hyper-excitability with better isoform selectivity.

A cladribine-cyclodextrin sublingual film bypasses GI degradation and first-pass metabolism to improve absorption for patients with dysphagia.

Blocking the CREB-heparan sulfate-FGF axis helps attenuate PTEN-loss prostate cancer growth by disrupting key oncogenic signaling.

By driving TFEB/TFE3 nuclear translocation, arimoclomol boosts NPC1 expression, clears lysosomal cholesterol, and slows NPC progression.

Aptamer-guided antisense oligonucleotides target PDAC cells to suppress KRAS and SOS1 mRNA while reducing toxicity to normal cells.